Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team Storage-Area Networking (SAN) DIEGO, ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, ...

Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio.Halozyme ...

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.

ADRs quickly rose 14% on a report that Halozyme Therapeutics (HALO) has expressed takeover interest. Halozyme has recently ...

Deutsche Bank analyst Falko Friedrichs maintained a Sell rating on Evotec (0IRF – Research Report) today and set a price target of ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

FRANKFURT: Europe’s main stock index logged its best day in six weeks on Monday, with defence stocks in the lead ...

Triton Partners, is considering a takeover bid Evotec , Eyk Henning of Bloomberg reported earlier, citing people familiar with the matter. Triton is among several investment firms ...

Germany-based Evotec SE (NASDAQ:EVO) is trading on Monday after a report that suggests the company is a takeover target. The ...